We are live on ! Find out more
PEAR

Pear Therapeutics, Inc. Class A Common Stock
PEAR

Delisted

PEAR was delisted on the 18th of April, 2023.

Back to rankings

72 hedge funds and large institutions have $203M invested in Pear Therapeutics, Inc. Class A Common Stock in 2021 Q2 according to their latest regulatory filings, with 55 funds opening new positions, 7 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

5,400% more first-time investments, than exits

New positions opened: 55 | Existing positions closed: 1

654% more capital invested

Capital invested by funds: $26.9M → $203M (+$176M)

600% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 1

300% more funds holding

Funds holding: 18 → 72 (+54)

Holders
72
Holders Change
+54
Holders Change %
+300%
% of All Funds
1.25%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
55
Increased
7
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CM
Cohanzick Management
New York
+$13.8M
2
RA
RiverPark Advisors
New York
+$12.8M
3
AC
Aristeia Capital
Connecticut
+$11.8M
4
Nomura Holdings
Nomura Holdings
Japan
+$11.5M
5
Citadel Advisors
Citadel Advisors
Florida
+$9.81M

Top Sellers

Rank Fund Capital Flow
1
OCM
Oribel Capital Management
New York
-$13.4K
2
BCM
Basso Capital Management
Connecticut
-$1K
Name Holding Trade Value Shares
Change 		Change in
Stake
WAM
51
Weiss Asset Management
Massachusetts
$494K +$490K +49,998 New
Toronto Dominion Bank
52
Toronto Dominion Bank
Ontario, Canada
$484K +$480K +48,925 New
BFM
53
Boothbay Fund Management
New York
$460K +$457K +46,557 New
LCM
54
Landscape Capital Management
New Jersey
$427K +$424K +43,253 New
Walleye Trading
55
Walleye Trading
New York
$395K +$392K +39,999 New
Jane Street
56
Jane Street
New York
$362K +$115K +11,706 +47%
ACM
57
Atalaya Capital Management
New York
$247K – – –
DCM
58
DG Capital Management
New York
$247K – – –
VI
59
Vestcor Inc
New Brunswick, Canada
$247K – – –
LC
60
Littlejohn & Co
Connecticut
$247K +$245K +25,000 New
OFG
61
OTA Financial Group
New York
$246K +$244K +24,931 New
BTP
62
Bloom Tree Partners
New York
$239K +$237K +24,202 New
MIG
63
Mariner Investment Group
New York
$198K +$196K +20,000 New
AC
64
Athanor Capital
New York
$148K +$147K +15,000 New
OCAM
65
Owl Creek Asset Management
New York
$123K – – –
AA
66
Ancora Advisors
Ohio
$99K +$98.1K +10,000 New
EIP
67
Easterly Investment Partners
Massachusetts
$99K +$98.1K +10,000 New
CAPTRUST Financial Advisors
68
CAPTRUST Financial Advisors
North Carolina
$56K +$55.6K +5,667 New
PAM
69
Panagora Asset Management
Massachusetts
$7K +$7.06K +720 New
MI
70
MMCAP International
Cayman Islands
$4.94K +$4.9M +500,000 New
FIA
71
FNY Investment Advisers
New York
$1K +$1.96K +200 New
Walleye Capital
72
Walleye Capital
New York
$673 +$668K +68,130 New
BCM
73
Basso Capital Management
Connecticut
– -$1K -100 Closed
1 2
3

PEAR Hedge Fund Activity: Q2 2021 in Review

72 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Pear Therapeutics, Inc. Class A Common Stock (PEAR) for Q2 2021, worth a combined $203M — up 654% from $26.9M a quarter earlier.

Buyers outnumbered sellers: 55 funds opened new PEAR positions and 1 closed out — a net gain of 54 holders — while 7 added to existing stakes and 1 trimmed.

The largest buyer was Cohanzick Management, opening a new position worth an estimated $13.8M. The largest seller was Oribel Capital Management, cutting an estimated $13.4K.

  • 72 institutional investors held Pear Therapeutics, Inc. Class A Common Stock (PEAR) as of Q2 2021, up from 18 in Q1 2021.
  • Funds reported $203M of Pear Therapeutics, Inc. Class A Common Stock stock for Q2 2021, up 654% quarter-over-quarter.
  • 55 funds opened new Pear Therapeutics, Inc. Class A Common Stock positions in Q2 2021 and 1 closed out, a net change of +54 holders.
  • The largest Pear Therapeutics, Inc. Class A Common Stock buyer in Q2 2021 was Cohanzick Management, an estimated $13.8M added.
  • The largest Pear Therapeutics, Inc. Class A Common Stock seller in Q2 2021 was Oribel Capital Management, an estimated $13.4K sold.

Based on aggregated 13F filings for Q2 2021.